TBPH — Theravance Biopharma Share News
0.000.00%
Last trade - 00:00- $857.84m
- $495.97m
- $107.46m
Theravance Biopharma tumbles as lung disease drug fails to meet main goal
Brief: Theravance Biopharma's Lung Disease Drug Fails to Meet Main Goal of Study
Brief: Theravance Biopharma- On Dec 26 Units, Mylan Ireland & Mylan Specialty L.P. Entered Settlement Agreement With Accord Healthcare
Brief: Theravance Biopharma Announces Appointment Of Jeremy Grant To Board Of Directors
Brief: Viatris And Theravance Biopharma Announce Positive Top-Line Results From Yupelri (Revefenacin) Phase III Trial
Theravance Biopharma Inc expected to post a loss of 21 cents a share - Earnings Preview
Theravance Biopharma Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: Theravance Biopharma Gets Notice From Pfizer Terminating License Agreement
Brief: Theravance Biopharma Announces Orphan Drug Designation Granted To Ampreloxetine
Brief: Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results
Theravance Biopharma Inc reports results for the quarter ended in March - Earnings Summary
Theravance Biopharma Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Weiss Asset Management Reports 11.79% Stake In Theravance Biopharma
Brief: Theravance Biopharma, Inc. Announces Appointment Of Jim Kelly, Managing Director At Weiss Asset Management, To Board Of Directors
Brief: Theravance Biopharma Says Does Not Hold Cash Deposits Or Securities At Silicon Valley Bank
Brief: Theravance Biopharma, Inc. Announces Strategic Actions And Reports Fourth Quarter / Full Year 2022 Financial Results And Business Update
Theravance Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Irenic Capital urges Theravance to conduct review, add shareholder to board (updated)
Brief: Irenic Sends Letter To Theravance Biopharma Regarding The Urgent Need For A Governance Overhaul, Capital Return And Strategic Review